Accessibility Menu
Vanda Pharmaceuticals Stock Quote

Vanda Pharmaceuticals (NASDAQ: VNDA)

$5.34
(0.9%)
+0.04
Price as of October 22, 2025, 3:58 p.m. ET

KEY DATA POINTS

Current Price
$5.34
Daily Change
(0.9%) +$0.04
Day's Range
$5.22 - $5.38
Previous Close
$5.34
Open
$5.32
Beta
0.74
Volume
514,379
Average Volume
493,659
Market Cap
315.5M
Market Cap / Employee
$5.34M
52wk Range
$3.81 - $5.59
Revenue
-
Gross Margin
0.91%
Dividend Yield
N/A
EPS
-$1.14
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Vanda Pharmaceuticals Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
VNDA+12.9%-47.9%-12.23%-45%
S&P+14.5%+93.32%+14.09%+420%

Vanda Pharmaceuticals Company Info

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$52.59M4.2%
Gross Profit$48.10M4.6%
Gross Margin91.47%0.4%
Market Cap$278.17M-15.4%
Market Cap / Employee$0.76M0.0%
Employees36881.3%
Net Income-$27.21M-502.2%
EBITDA-$36.49M-346.1%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$80.98M-21.3%
Accounts Receivable$44.99M7.5%
Inventory2.247.7%

Liabilities

Q2 2025YOY Change
Long Term Debt$6.96M15.9%
Short Term Debt$4.68M92.8%

Ratios

Q2 2025YOY Change
Return On Assets-10.49%-8.8%
Return On Invested Capital1.93%-6.1%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$15.55M-121.0%
Operating Free Cash Flow-$15.25M-120.2%

Valuation

MetricQ4 2023YoY Change
Price to Earnings96.57-
Price to Book0.510.520.500.54-10.01%
Price to Sales1.431.411.331.37-24.27%
Price to Tangible Book Value0.640.660.630.70-9.98%
Price to Free Cash Flow TTM19.55-
Enterprise Value to EBITDA10.539.991.550.97-84.20%
Free Cash Flow Yield5.1%-
Return on Equity-3.0%-3.5%-8.4%-13.0%544.48%
Total Debt$7.94M$12.36M$11.75M$11.64M38.04%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.